1Genomic Instability Group, Spanish National Cancer Research Center, Madrid 28029, Spain.
2Laboratory of Genome Integrity, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
3AstraZeneca, Cambridge CB4 0WG, UK.
4Human Oncology and Pathogenesis Program and Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
5Science for Life Laboratory, Division of Translational Medicine and Chemical Biology, Department of Medical Biochemistry and Biophysics, Karolinska Institute, Solna 17165, Sweden.
1Genomic Instability Group, Spanish National Cancer Research Center, Madrid 28029, Spain.
5Science for Life Laboratory, Division of Translational Medicine and Chemical Biology, Department of Medical Biochemistry and Biophysics, Karolinska Institute, Solna 17165, Sweden.
By Isabel Morgado-Palacin, Amanda Day, Matilde Murga, Vanesa Lafarga, Marta Elena Anton, Anthony Tubbs, Hua-Tang Chen, Aysegul V. Ergen, Rhonda Anderson, Avinash Bhandoola, Kurt G. Pike, Bernard Barlaam, Elaine Cadogan, Xi Wang, Andrew J. Pierce, Chad Hubbard, Scott A. Armstrong, André Nussenzweig, Oscar Fernandez-Capetillo
Science Signaling : ra91
Chemotherapy-resistant acute myeloid leukemia may respond to inhibition of ATR or ATM.
By Isabel Morgado-Palacin, Amanda Day, Matilde Murga, Vanesa Lafarga, Marta Elena Anton, Anthony Tubbs, Hua-Tang Chen, Aysegul V. Ergen, Rhonda Anderson, Avinash Bhandoola, Kurt G. Pike, Bernard Barlaam, Elaine Cadogan, Xi Wang, Andrew J. Pierce, Chad Hubbard, Scott A. Armstrong, André Nussenzweig, Oscar Fernandez-Capetillo
Science Signaling : ra91
Chemotherapy-resistant acute myeloid leukemia may respond to inhibition of ATR or ATM.